View Future GrowthUniverse Pharmaceuticals 과거 순이익 실적과거 기준 점검 0/6Universe Pharmaceuticals 의 수입은 연평균 -47%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 연평균 9.4%의 비율로 증가했습니다. 매출은 연평균 15.7%의 비율로 감소해 왔습니다.핵심 정보-47.02%순이익 성장률98.72%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률5.95%매출 성장률-15.66%자기자본이익률-6.54%순이익률-20.56%최근 순이익 업데이트30 Sep 2025최근 과거 실적 업데이트Reported Earnings • Feb 04Full year 2025 earnings released: US$8.06 loss per share (vs US$627 loss in FY 2024)Full year 2025 results: US$8.06 loss per share (improved from US$627 loss in FY 2024). Revenue: US$17.9m (down 22% from FY 2024). Net loss: US$3.67m (loss narrowed 58% from FY 2024).Reported Earnings • Jul 07First half 2025 earnings releasedFirst half 2025 results: US$9.44 loss per share. Revenue: US$9.15m (down 29% from 1H 2024). Net loss: US$3.28m (loss narrowed 75% from 1H 2024).Reported Earnings • May 01Full year 2024 earnings releasedFull year 2024 results: US$627 loss per share. Revenue: US$23.0m (down 29% from FY 2023). Net loss: US$8.73m (loss widened 42% from FY 2023).Reported Earnings • Feb 01Full year 2023 earnings released: US$1.70 loss per share (vs US$2.41 loss in FY 2022)Full year 2023 results: US$1.70 loss per share (improved from US$2.41 loss in FY 2022). Revenue: US$32.3m (down 20% from FY 2022). Net loss: US$6.16m (loss narrowed 30% from FY 2022).Reported Earnings • Aug 18First half 2022 earnings released: EPS: US$0.08 (vs US$0.44 in 1H 2021)First half 2022 results: EPS: US$0.08 (down from US$0.44 in 1H 2021). Revenue: US$24.2m (flat on 1H 2021). Net income: US$1.73m (down 76% from 1H 2021). Profit margin: 7.2% (down from 29% in 1H 2021).Reported Earnings • Feb 02Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: US$0.60 (up from US$0.47 in FY 2020). Revenue: US$48.0m (up 56% from FY 2020). Net income: US$11.3m (up 50% from FY 2020). Profit margin: 24% (down from 25% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates.모든 업데이트 보기Recent updatesReported Earnings • Feb 04Full year 2025 earnings released: US$8.06 loss per share (vs US$627 loss in FY 2024)Full year 2025 results: US$8.06 loss per share (improved from US$627 loss in FY 2024). Revenue: US$17.9m (down 22% from FY 2024). Net loss: US$3.67m (loss narrowed 58% from FY 2024).New Risk • Jan 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 60% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 9x increase in shares outstanding). Market cap is less than US$10m (US$2.54m market cap). Minor Risk Latest financial reports are more than 6 months old (reported March 2025 fiscal period end).분석 기사 • Nov 25Investors Don't See Light At End Of Universe Pharmaceuticals INC's (NASDAQ:UPC) Tunnel And Push Stock Down 31%Universe Pharmaceuticals INC ( NASDAQ:UPC ) shares have had a horrible month, losing 31% after a relatively good period...New Risk • Oct 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings have declined by 60% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 13x increase in shares outstanding). Market cap is less than US$10m (US$2.91m market cap).분석 기사 • Sep 10Universe Pharmaceuticals INC's (NASDAQ:UPC) Prospects Need A Boost To Lift SharesYou may think that with a price-to-sales (or "P/S") ratio of 0.1x Universe Pharmaceuticals INC ( NASDAQ:UPC ) is...공시 • Jul 30Universe Pharmaceuticals INC, Annual General Meeting, Aug 26, 2025Universe Pharmaceuticals INC, Annual General Meeting, Aug 26, 2025, at 10:00 China Standard Time. Location: 265 jingjiu avenue, jinggangshan economy and technology, development zone, jiangxi 343100., jian ChinaReported Earnings • Jul 07First half 2025 earnings releasedFirst half 2025 results: US$9.44 loss per share. Revenue: US$9.15m (down 29% from 1H 2024). Net loss: US$3.28m (loss narrowed 75% from 1H 2024).분석 기사 • May 20Universe Pharmaceuticals INC's (NASDAQ:UPC) Price Is Right But Growth Is Lacking After Shares Rocket 77%Universe Pharmaceuticals INC ( NASDAQ:UPC ) shares have had a really impressive month, gaining 77% after a shaky period...분석 기사 • May 20Improved Revenues Required Before Universe Pharmaceuticals INC (NASDAQ:UPC) Stock's 77% Jump Looks JustifiedUniverse Pharmaceuticals INC ( NASDAQ:UPC ) shares have had a really impressive month, gaining 77% after a shaky period...Reported Earnings • May 01Full year 2024 earnings releasedFull year 2024 results: US$627 loss per share. Revenue: US$23.0m (down 29% from FY 2023). Net loss: US$8.73m (loss widened 42% from FY 2023).공시 • Feb 26Universe Pharmaceuticals Receives Staff Determination Notice from Nasdaq Related to Delayed Annual ReportUniverse Pharmaceuticals INC (the “Company”) announced that on February 19, 2025, the Company received a staff determination notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it is delinquent in filing its Annual Report on Form 20-F for the fiscal year ended September 30, 2024 (the “Form 20-F”) and that this matter serves as an additional basis for delisting the Company’s securities from Nasdaq. The failure to timely file the Form 20-F is a violation of Nasdaq Listing Rule 5250(c)(1). The Company is before a Hearings Panel for its failure to comply with Listing Rule 5550(a)(2) and was therefore provided until February 26, 2025 to request a stay of the suspension of the Company’s securities, pending a Hearings Panel decision. The Company intends to request a stay of the suspension before that date. The Company is working on completing and filing the delayed Form 20-F. This announcement is being made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.공시 • Feb 04Universe Pharmaceuticals Receives Nasdaq Delisting Notice Subject to Hearing RequestUniverse Pharmaceuticals INC announced that the Company received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) on January 29, 2025, notifying the Company that the Nasdaq staff has determined to delist the Company’s ordinary shares from The Nasdaq Capital Market (the “Delisting Determination”), because the bid price of the Company’s listed securities has closed at less than $1 per share over the previous 30 consecutive business days, and therefore no longer complies with the Nasdaq Listing Rule 5550(a)(2) (the “Rule”). Normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the Rule. However, pursuant to the Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Company is not eligible for any compliance period specified in Nasdaq Listing Rule 5810(c)(3)(A) due to the fact that the Company effected a reverse stock split on November 18, 2024, or within the prior one-year period. The Company was provided until February 5, 2025 to request an appeal of the Delisting Determination to the hearing panel. The Company intends to request such hearing to appeal the Delisting Determination before that date, which will stay the suspension of its securities from the date of the request, during which time such securities will continue to be listed on The Nasdaq Capital Market. If the Company fails to request an appeal of the Delisting Determination by February 5, 2025, trading of the Company’s ordinary shares will be suspended at the opening of business on February 7, 2025, and a Form 25-NSE will be filed with the U.S. Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market. The Company is considering all potential options available to it to regain compliance with the aforementioned rules, including seeking shareholders’ approval for a reverse stock split.공시 • Jan 28Universe Pharmaceuticals INC announced delayed 20-F filingOn 01/27/2025, Universe Pharmaceuticals INC announced that they will be unable to file their next 20-F by the deadline required by the SEC.공시 • Dec 12Universe Pharmaceuticals INC has completed a Follow-on Equity Offering in the amount of $14.981638 million.Universe Pharmaceuticals INC has completed a Follow-on Equity Offering in the amount of $14.981638 million. Security Name: Ordinary Share Security Type: Common Stock Securities Offered: 388,000 Price\Range: $0.8 Discount Per Security: $0.056 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 18,362,000 Price\Range: $0.799 Discount Per Security: $0.05593 Security Name: Common Warrants Security Type: Equity Warrant Transaction Features: Registered Direct Offering분석 기사 • Nov 14Universe Pharmaceuticals INC (NASDAQ:UPC) Not Doing Enough For Some Investors As Its Shares Slump 44%Unfortunately for some shareholders, the Universe Pharmaceuticals INC ( NASDAQ:UPC ) share price has dived 44% in the...분석 기사 • Sep 27Why Investors Shouldn't Be Surprised By Universe Pharmaceuticals INC's (NASDAQ:UPC) 92% Share Price PlungeUniverse Pharmaceuticals INC ( NASDAQ:UPC ) shareholders that were waiting for something to happen have been dealt a...New Risk • Sep 18New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.34m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 53% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (US$9.34m market cap). Minor Risk Latest financial reports are more than 6 months old (reported September 2023 fiscal period end).공시 • Sep 05Universe Pharmaceuticals INC, Annual General Meeting, Sep 27, 2024Universe Pharmaceuticals INC, Annual General Meeting, Sep 27, 2024, at 10:00 China Standard Time. Location: 265 jingjiu avenue, jinggangshan economy and, technology development zone, jiangxi 343100, jian city, ChinaNew Risk • Aug 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 53% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (US$89.1m market cap).분석 기사 • Jul 22Universe Pharmaceuticals INC's (NASDAQ:UPC) 41% Price Boost Is Out Of Tune With RevenuesDespite an already strong run, Universe Pharmaceuticals INC ( NASDAQ:UPC ) shares have been powering on, with a gain of...New Risk • Jul 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 5x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 53% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$58.9m market cap).분석 기사 • May 22Universe Pharmaceuticals INC's (NASDAQ:UPC) Price Is Right But Growth Is Lacking After Shares Rocket 31%Universe Pharmaceuticals INC ( NASDAQ:UPC ) shares have continued their recent momentum with a 31% gain in the last...Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Xiao Pang was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.공시 • Apr 26Universe Pharmaceuticals INC has filed a Follow-on Equity Offering in the amount of $25 million.Universe Pharmaceuticals INC has filed a Follow-on Equity Offering in the amount of $25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: $1.25 Discount Per Security: $0분석 기사 • Apr 07Universe Pharmaceuticals INC's (NASDAQ:UPC) Shares Bounce 27% But Its Business Still Trails The IndustryUniverse Pharmaceuticals INC ( NASDAQ:UPC ) shareholders are no doubt pleased to see that the share price has bounced...분석 기사 • Feb 07Investors Don't See Light At End Of Universe Pharmaceuticals INC's (NASDAQ:UPC) Tunnel And Push Stock Down 27%Universe Pharmaceuticals INC ( NASDAQ:UPC ) shares have retraced a considerable 27% in the last month, reversing a fair...Reported Earnings • Feb 01Full year 2023 earnings released: US$1.70 loss per share (vs US$2.41 loss in FY 2022)Full year 2023 results: US$1.70 loss per share (improved from US$2.41 loss in FY 2022). Revenue: US$32.3m (down 20% from FY 2022). Net loss: US$6.16m (loss narrowed 30% from FY 2022).분석 기사 • Dec 18There's No Escaping Universe Pharmaceuticals INC's (NASDAQ:UPC) Muted Revenues Despite A 54% Share Price RiseUniverse Pharmaceuticals INC ( NASDAQ:UPC ) shares have had a really impressive month, gaining 54% after a shaky period...New Risk • Aug 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 28% per year over the past 5 years. Market cap is less than US$10m (US$5.69m market cap). Minor Risk Latest financial reports are more than 6 months old (reported September 2022 fiscal period end).New Risk • Jun 22New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.79m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 28% per year over the past 5 years. Market cap is less than US$10m (US$9.79m market cap).New Risk • Jun 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 28% per year over the past 5 years. Minor Risk Market cap is less than US$100m (US$11.3m market cap).공시 • May 25Universe Pharmaceuticals INC, Annual General Meeting, Jul 03, 2023Universe Pharmaceuticals INC, Annual General Meeting, Jul 03, 2023, at 10:00 China Standard Time. Location: 265 Jingjiu Avenue,Jinggangshan Economy and Technology Development Zone , Ji’an City, Jiangxi 343100, the People’s Republic of China Hong Kong China Agenda: To discuss re-elect Gang Lai as a director of the Company to hold office until the next annual general meeting of the Company; to re-elect Lin Yang as a director of the Company; to re-elect Jiawen Pang as a director of the Company; to re-elect Ding Zheng as a director of the Company ; to approve the increase of the Company’ s authorized share capital, effective immediately; and to discuss other matters.공시 • May 06Universe Pharmaceuticals INC Announces Board ChangesUniverse Pharmaceuticals INC announced that on April 24, 2023, Mr. David Sherman, the Directors of the Company, notified the Company of his resignation as a director of the Company and the chairman of the audit committee of the board of directors, effective May 2, 2023. On May 3, 2023, the Company’s board of directors appointed Mr. Yongping Yu as a director of the Company and the chairman of the nominating and corporate governance committee of the board of directors. The board of directors also appointed Mr. Ding Zheng, a director of the company and the then chairman of the nominating and corporate governance committee of the board of directors, as the chairman of the audit committee of the board of directors. The appointments intend to fill the vacancy created by Mr. David Sherman’s departure. Mr. Yongping Yu has served as one of the Company’s independent directors since May 2023. Mr. Yongping Yu has served as the General Manager of Zhuhai Qirong Venture Capital Investment Management Co. Ltd. since August 2019, a venture capital company focused on the healthcare industry. Mr. Yongping Yu served as a director and Executive Deputy General Manager of Xinhua Kangmei Health Think Tank Co. Ltd. from May 2017 to July 2019. From July 2015 to May 2017, Mr. Yongping Yu served as the General Manager of the Medical Data Division of Xinhua News Agency’s Big Data Business Department. From July 2014 to July 2015, Mr. Yongping Yu served as the Editor-in-Chief and General Manager of Xinhua Cyber Health, a WeChat official account, at Xinhua News Agency. From February 2011 to July 2014, Mr. Yongping Yu served as the Director of the Development Planning Department and Chief Physician of the Aviation General Hospital. From April 2004 to February 2011, Mr. Yongping Yu served as the Deputy Secretary-General of JiangXi Pharmaceutical Association. Mr. Yu obtained a Bachelor of Medicine degree from Nanchang University in the PRC in 1992 and obtained Bachelor of Arts degree in Chinese language and literature from Tsinghua University in the PRC in 1995.공시 • Jan 31Universe Pharmaceuticals INC announced delayed 20-F filingOn 01/30/2023, Universe Pharmaceuticals INC announced that they will be unable to file their next 20-F by the deadline required by the SEC.Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to US$1.69, the stock trades at a trailing P/E ratio of 6.2x. Average trailing P/E is 17x in the Pharmaceuticals industry in the US. Total returns to shareholders of 5.4% over the past year.공시 • Dec 22Universe Pharmaceuticals INC Announces Inclusion of Six Products into the First Edition of Catalogue of Medicine for Patients Infected with COVID-19Universe Pharmaceuticals INC announced that six varieties of the Company's products were included in the First Edition of Catalogue of Medicine for Patients Infected with COVID-19 which was published by Beijing Health Commission on December 12, 2022. The included products are Banlangen Granules, Strong Loquat Extract, Pediatric Paracetamol, Vitamin C Yinqiao Tablets, Acetaminophen Tablets and Metamizole Sodium Tablets. The Catalogue supplements the list of recommended medicine in the Ninth Edition of the National Diagnosis and Treatment Plan. The Catalogue recommends 67 types of traditional Chinese medicine products for six different types ofmedical symptoms, such as fever and sore throat, and recommends 41 varieties of western medicine products for four types of clinical symptoms, such as cough and expectoration. In addition to hospitals, patients can also purchase medicines included in the Catalogue from channels such as retail pharmacies and e-commerce platforms according to their own needs.Valuation Update With 7 Day Price Move • Nov 30Investor sentiment improved over the past weekAfter last week's 18% share price gain to US$1.76, the stock trades at a trailing P/E ratio of 6.5x. Average trailing P/E is 16x in the Pharmaceuticals industry in the US. Total loss to shareholders of 19% over the past year.공시 • Nov 15Universe Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementUniverse Pharmaceuticals INC announced that the Company received a written notification (the “Notification Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) on November 9, 2022, informing the Company that it has regained compliance with the Nasdaq’s minimum bid price requirement and the matter is closed. On July 15, 2022, the Company was notified by Nasdaq its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive business days under Nasdaq Listing Rules 5450(a)(1) and 5810(c)(3)(A), and was provided 180 calendar days, or until January 11, 2023 to regain compliance. The Notification Letter the Company received from Nasdaq on November 9, 2022 noted that the Company evidenced a closing bid price of its ordinary shares at or greater than the $1.00 per share minimum requirement for the last 10 consecutive business days, from October 26, 2022 through November 8, 2022. Nasdaq stated that accordingly, the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1).Valuation Update With 7 Day Price Move • Oct 21Investor sentiment improved over the past weekAfter last week's 27% share price gain to US$1.05, the stock trades at a trailing P/E ratio of 3.9x. Average trailing P/E is 13x in the Pharmaceuticals industry in the US. Total loss to shareholders of 55% over the past year.공시 • Aug 30Universe Pharmaceuticals INC, Annual General Meeting, Sep 23, 2022Universe Pharmaceuticals INC, Annual General Meeting, Sep 23, 2022, at 10:00 China Standard Time. Location: 265 Jingjiu Avenue, Jinggangshan Economy and Technology Development Zone, Ji'an City Ji'an City China Agenda: To re-elect directors; to approve of the proposed filing of a shelf registration statement on Form F-3 registering the Company's ordinary shares, preferred shares, debt securities, warrants, rights and units of up to $200 million; to re-designate 10,000,000 authorized but unissued ordinary shares of the Company; to adopt a second amended and restated memorandum and articles of association; to authorize board of directors to effect a consolidation of the Company's authorized and issued share capital; to consider subject to approval by the shareholders of the Share Consolidation, and entirely conditional upon the effectiveness of the Share Consolidation, with effect as of the date the Company's board of directors may determine in its sole discretion, the Company adopt a third amended and restated memorandum of association.Reported Earnings • Aug 18First half 2022 earnings released: EPS: US$0.08 (vs US$0.44 in 1H 2021)First half 2022 results: EPS: US$0.08 (down from US$0.44 in 1H 2021). Revenue: US$24.2m (flat on 1H 2021). Net income: US$1.73m (down 76% from 1H 2021). Profit margin: 7.2% (down from 29% in 1H 2021).공시 • Jul 20Universe Pharmaceuticals Inc Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyUniverse Pharmaceuticals INC announced that the Company received a written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) on July 15, 2022, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's ordinary shares for the 30 consecutive business days from June 1, 2022 to July 14, 2022, the Company no longer meets the minimum bid price requirement. The Notification Letter does not impact the Company's listing on the Nasdaq Global Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until January 11, 2023, to regain compliance with Nasdaq Listing Rule 5450(a)(1). To regain compliance, the Company's ordinary shares must have a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. In the event the Company does not regain compliance by January 11, 2023, the Company may be eligible for additional time to regain compliance or may face delisting.Seeking Alpha • Jul 19Universe pharmaceuticals receives Nasdaq notification regarding minimum bid price deficiencyUniverse Pharmaceuticals (NASDAQ:UPC) received Nasdaq notification on July 15, 2022, notifying the company that it is not in compliance with the minimum bid price requirement. The company has 180 days to regain compliance. If the company does not regain compliance by January 11, 2023, the company may be eligible for additional time to regain compliance or may face delisting. The Company intends to monitor the closing bid price of its ordinary shares and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse share split of its outstanding ordinary shares, to regain compliance.Valuation Update With 7 Day Price Move • Mar 12Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to US$1.09, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 20x in the Pharmaceuticals industry in the US.분석 기사 • Feb 21Improved Earnings Required Before Universe Pharmaceuticals INC (NASDAQ:UPC) Shares Find Their FeetWhen close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 17x, you may...Reported Earnings • Feb 02Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: US$0.60 (up from US$0.47 in FY 2020). Revenue: US$48.0m (up 56% from FY 2020). Net income: US$11.3m (up 50% from FY 2020). Profit margin: 24% (down from 25% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates.Valuation Update With 7 Day Price Move • Jan 25Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to US$1.36, the stock trades at a trailing P/E ratio of 3.1x. Average trailing P/E is 23x in the Pharmaceuticals industry in the US.Valuation Update With 7 Day Price Move • Dec 03Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to US$1.88, the stock trades at a trailing P/E ratio of 4.2x. Average trailing P/E is 23x in the Pharmaceuticals industry in the US.분석 기사 • Aug 10We Think That There Are Some Issues For Universe Pharmaceuticals (NASDAQ:UPC) Beyond Its Promising EarningsUniverse Pharmaceuticals INC's ( NASDAQ:UPC ) healthy profit numbers didn't contain any surprises for investors. We...Reported Earnings • Aug 04First half 2021 earnings released: EPS US$0.44 (vs US$0.32 in 1H 2020)The company reported a solid first half result with improved earnings and revenues, although profit margins were weaker. First half 2021 results: Revenue: US$24.3m (up 48% from 1H 2020). Net income: US$7.15m (up 41% from 1H 2020). Profit margin: 29% (down from 31% in 1H 2020). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Jul 23Investor sentiment improved over the past weekAfter last week's 40% share price gain to US$3.83, the stock trades at a trailing P/E ratio of 8.1x. Average trailing P/E is 21x in the Pharmaceuticals industry in the US.Valuation Update With 7 Day Price Move • Jun 30Investor sentiment improved over the past weekAfter last week's 22% share price gain to US$3.70, the stock trades at a trailing P/E ratio of 7.8x. Average trailing P/E is 22x in the Pharmaceuticals industry in the US.Valuation Update With 7 Day Price Move • Apr 14Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to US$4.09, the stock trades at a trailing P/E ratio of 8.7x. Average trailing P/E is 27x in the Pharmaceuticals industry in the US.매출 및 비용 세부 내역Universe Pharmaceuticals가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqCM:UPC 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Sep 2518-49130 Jun 2519410231 Mar 2519-1011331 Dec 2421-911330 Sep 2423-911330 Jun 2425-1911331 Mar 2427-1910331 Dec 2330-1210430 Sep 2332-79530 Jun 2333-812731 Mar 2334-11141031 Dec 2237-1018930 Sep 2240-821830 Jun 2244-118631 Mar 2248615531 Dec 2148911530 Sep 2148116530 Jun 2143105331 Mar 2139104031 Dec 203594030 Sep 203183130 Jun 203183131 Mar 203193131 Dec 193283130 Sep 193383130 Sep 1829831양질의 수익: UPC 은(는) 현재 수익성이 없습니다.이익 마진 증가: UPC는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: UPC은 수익성이 없으며 지난 5년 동안 손실이 연평균 47% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 UPC의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: UPC은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(-4.8%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: UPC는 현재 수익성이 없으므로 자본 수익률이 음수(-6.54%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/27 23:35종가2026/05/27 00:00수익2025/09/30연간 수익2025/09/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Universe Pharmaceuticals INC는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Feb 04Full year 2025 earnings released: US$8.06 loss per share (vs US$627 loss in FY 2024)Full year 2025 results: US$8.06 loss per share (improved from US$627 loss in FY 2024). Revenue: US$17.9m (down 22% from FY 2024). Net loss: US$3.67m (loss narrowed 58% from FY 2024).
Reported Earnings • Jul 07First half 2025 earnings releasedFirst half 2025 results: US$9.44 loss per share. Revenue: US$9.15m (down 29% from 1H 2024). Net loss: US$3.28m (loss narrowed 75% from 1H 2024).
Reported Earnings • May 01Full year 2024 earnings releasedFull year 2024 results: US$627 loss per share. Revenue: US$23.0m (down 29% from FY 2023). Net loss: US$8.73m (loss widened 42% from FY 2023).
Reported Earnings • Feb 01Full year 2023 earnings released: US$1.70 loss per share (vs US$2.41 loss in FY 2022)Full year 2023 results: US$1.70 loss per share (improved from US$2.41 loss in FY 2022). Revenue: US$32.3m (down 20% from FY 2022). Net loss: US$6.16m (loss narrowed 30% from FY 2022).
Reported Earnings • Aug 18First half 2022 earnings released: EPS: US$0.08 (vs US$0.44 in 1H 2021)First half 2022 results: EPS: US$0.08 (down from US$0.44 in 1H 2021). Revenue: US$24.2m (flat on 1H 2021). Net income: US$1.73m (down 76% from 1H 2021). Profit margin: 7.2% (down from 29% in 1H 2021).
Reported Earnings • Feb 02Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: US$0.60 (up from US$0.47 in FY 2020). Revenue: US$48.0m (up 56% from FY 2020). Net income: US$11.3m (up 50% from FY 2020). Profit margin: 24% (down from 25% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates.
Reported Earnings • Feb 04Full year 2025 earnings released: US$8.06 loss per share (vs US$627 loss in FY 2024)Full year 2025 results: US$8.06 loss per share (improved from US$627 loss in FY 2024). Revenue: US$17.9m (down 22% from FY 2024). Net loss: US$3.67m (loss narrowed 58% from FY 2024).
New Risk • Jan 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 60% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 9x increase in shares outstanding). Market cap is less than US$10m (US$2.54m market cap). Minor Risk Latest financial reports are more than 6 months old (reported March 2025 fiscal period end).
분석 기사 • Nov 25Investors Don't See Light At End Of Universe Pharmaceuticals INC's (NASDAQ:UPC) Tunnel And Push Stock Down 31%Universe Pharmaceuticals INC ( NASDAQ:UPC ) shares have had a horrible month, losing 31% after a relatively good period...
New Risk • Oct 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings have declined by 60% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 13x increase in shares outstanding). Market cap is less than US$10m (US$2.91m market cap).
분석 기사 • Sep 10Universe Pharmaceuticals INC's (NASDAQ:UPC) Prospects Need A Boost To Lift SharesYou may think that with a price-to-sales (or "P/S") ratio of 0.1x Universe Pharmaceuticals INC ( NASDAQ:UPC ) is...
공시 • Jul 30Universe Pharmaceuticals INC, Annual General Meeting, Aug 26, 2025Universe Pharmaceuticals INC, Annual General Meeting, Aug 26, 2025, at 10:00 China Standard Time. Location: 265 jingjiu avenue, jinggangshan economy and technology, development zone, jiangxi 343100., jian China
Reported Earnings • Jul 07First half 2025 earnings releasedFirst half 2025 results: US$9.44 loss per share. Revenue: US$9.15m (down 29% from 1H 2024). Net loss: US$3.28m (loss narrowed 75% from 1H 2024).
분석 기사 • May 20Universe Pharmaceuticals INC's (NASDAQ:UPC) Price Is Right But Growth Is Lacking After Shares Rocket 77%Universe Pharmaceuticals INC ( NASDAQ:UPC ) shares have had a really impressive month, gaining 77% after a shaky period...
분석 기사 • May 20Improved Revenues Required Before Universe Pharmaceuticals INC (NASDAQ:UPC) Stock's 77% Jump Looks JustifiedUniverse Pharmaceuticals INC ( NASDAQ:UPC ) shares have had a really impressive month, gaining 77% after a shaky period...
Reported Earnings • May 01Full year 2024 earnings releasedFull year 2024 results: US$627 loss per share. Revenue: US$23.0m (down 29% from FY 2023). Net loss: US$8.73m (loss widened 42% from FY 2023).
공시 • Feb 26Universe Pharmaceuticals Receives Staff Determination Notice from Nasdaq Related to Delayed Annual ReportUniverse Pharmaceuticals INC (the “Company”) announced that on February 19, 2025, the Company received a staff determination notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it is delinquent in filing its Annual Report on Form 20-F for the fiscal year ended September 30, 2024 (the “Form 20-F”) and that this matter serves as an additional basis for delisting the Company’s securities from Nasdaq. The failure to timely file the Form 20-F is a violation of Nasdaq Listing Rule 5250(c)(1). The Company is before a Hearings Panel for its failure to comply with Listing Rule 5550(a)(2) and was therefore provided until February 26, 2025 to request a stay of the suspension of the Company’s securities, pending a Hearings Panel decision. The Company intends to request a stay of the suspension before that date. The Company is working on completing and filing the delayed Form 20-F. This announcement is being made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.
공시 • Feb 04Universe Pharmaceuticals Receives Nasdaq Delisting Notice Subject to Hearing RequestUniverse Pharmaceuticals INC announced that the Company received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) on January 29, 2025, notifying the Company that the Nasdaq staff has determined to delist the Company’s ordinary shares from The Nasdaq Capital Market (the “Delisting Determination”), because the bid price of the Company’s listed securities has closed at less than $1 per share over the previous 30 consecutive business days, and therefore no longer complies with the Nasdaq Listing Rule 5550(a)(2) (the “Rule”). Normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the Rule. However, pursuant to the Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Company is not eligible for any compliance period specified in Nasdaq Listing Rule 5810(c)(3)(A) due to the fact that the Company effected a reverse stock split on November 18, 2024, or within the prior one-year period. The Company was provided until February 5, 2025 to request an appeal of the Delisting Determination to the hearing panel. The Company intends to request such hearing to appeal the Delisting Determination before that date, which will stay the suspension of its securities from the date of the request, during which time such securities will continue to be listed on The Nasdaq Capital Market. If the Company fails to request an appeal of the Delisting Determination by February 5, 2025, trading of the Company’s ordinary shares will be suspended at the opening of business on February 7, 2025, and a Form 25-NSE will be filed with the U.S. Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market. The Company is considering all potential options available to it to regain compliance with the aforementioned rules, including seeking shareholders’ approval for a reverse stock split.
공시 • Jan 28Universe Pharmaceuticals INC announced delayed 20-F filingOn 01/27/2025, Universe Pharmaceuticals INC announced that they will be unable to file their next 20-F by the deadline required by the SEC.
공시 • Dec 12Universe Pharmaceuticals INC has completed a Follow-on Equity Offering in the amount of $14.981638 million.Universe Pharmaceuticals INC has completed a Follow-on Equity Offering in the amount of $14.981638 million. Security Name: Ordinary Share Security Type: Common Stock Securities Offered: 388,000 Price\Range: $0.8 Discount Per Security: $0.056 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 18,362,000 Price\Range: $0.799 Discount Per Security: $0.05593 Security Name: Common Warrants Security Type: Equity Warrant Transaction Features: Registered Direct Offering
분석 기사 • Nov 14Universe Pharmaceuticals INC (NASDAQ:UPC) Not Doing Enough For Some Investors As Its Shares Slump 44%Unfortunately for some shareholders, the Universe Pharmaceuticals INC ( NASDAQ:UPC ) share price has dived 44% in the...
분석 기사 • Sep 27Why Investors Shouldn't Be Surprised By Universe Pharmaceuticals INC's (NASDAQ:UPC) 92% Share Price PlungeUniverse Pharmaceuticals INC ( NASDAQ:UPC ) shareholders that were waiting for something to happen have been dealt a...
New Risk • Sep 18New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.34m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 53% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (US$9.34m market cap). Minor Risk Latest financial reports are more than 6 months old (reported September 2023 fiscal period end).
공시 • Sep 05Universe Pharmaceuticals INC, Annual General Meeting, Sep 27, 2024Universe Pharmaceuticals INC, Annual General Meeting, Sep 27, 2024, at 10:00 China Standard Time. Location: 265 jingjiu avenue, jinggangshan economy and, technology development zone, jiangxi 343100, jian city, China
New Risk • Aug 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 53% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (US$89.1m market cap).
분석 기사 • Jul 22Universe Pharmaceuticals INC's (NASDAQ:UPC) 41% Price Boost Is Out Of Tune With RevenuesDespite an already strong run, Universe Pharmaceuticals INC ( NASDAQ:UPC ) shares have been powering on, with a gain of...
New Risk • Jul 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 5x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 53% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$58.9m market cap).
분석 기사 • May 22Universe Pharmaceuticals INC's (NASDAQ:UPC) Price Is Right But Growth Is Lacking After Shares Rocket 31%Universe Pharmaceuticals INC ( NASDAQ:UPC ) shares have continued their recent momentum with a 31% gain in the last...
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Xiao Pang was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
공시 • Apr 26Universe Pharmaceuticals INC has filed a Follow-on Equity Offering in the amount of $25 million.Universe Pharmaceuticals INC has filed a Follow-on Equity Offering in the amount of $25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: $1.25 Discount Per Security: $0
분석 기사 • Apr 07Universe Pharmaceuticals INC's (NASDAQ:UPC) Shares Bounce 27% But Its Business Still Trails The IndustryUniverse Pharmaceuticals INC ( NASDAQ:UPC ) shareholders are no doubt pleased to see that the share price has bounced...
분석 기사 • Feb 07Investors Don't See Light At End Of Universe Pharmaceuticals INC's (NASDAQ:UPC) Tunnel And Push Stock Down 27%Universe Pharmaceuticals INC ( NASDAQ:UPC ) shares have retraced a considerable 27% in the last month, reversing a fair...
Reported Earnings • Feb 01Full year 2023 earnings released: US$1.70 loss per share (vs US$2.41 loss in FY 2022)Full year 2023 results: US$1.70 loss per share (improved from US$2.41 loss in FY 2022). Revenue: US$32.3m (down 20% from FY 2022). Net loss: US$6.16m (loss narrowed 30% from FY 2022).
분석 기사 • Dec 18There's No Escaping Universe Pharmaceuticals INC's (NASDAQ:UPC) Muted Revenues Despite A 54% Share Price RiseUniverse Pharmaceuticals INC ( NASDAQ:UPC ) shares have had a really impressive month, gaining 54% after a shaky period...
New Risk • Aug 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 28% per year over the past 5 years. Market cap is less than US$10m (US$5.69m market cap). Minor Risk Latest financial reports are more than 6 months old (reported September 2022 fiscal period end).
New Risk • Jun 22New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.79m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 28% per year over the past 5 years. Market cap is less than US$10m (US$9.79m market cap).
New Risk • Jun 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 28% per year over the past 5 years. Minor Risk Market cap is less than US$100m (US$11.3m market cap).
공시 • May 25Universe Pharmaceuticals INC, Annual General Meeting, Jul 03, 2023Universe Pharmaceuticals INC, Annual General Meeting, Jul 03, 2023, at 10:00 China Standard Time. Location: 265 Jingjiu Avenue,Jinggangshan Economy and Technology Development Zone , Ji’an City, Jiangxi 343100, the People’s Republic of China Hong Kong China Agenda: To discuss re-elect Gang Lai as a director of the Company to hold office until the next annual general meeting of the Company; to re-elect Lin Yang as a director of the Company; to re-elect Jiawen Pang as a director of the Company; to re-elect Ding Zheng as a director of the Company ; to approve the increase of the Company’ s authorized share capital, effective immediately; and to discuss other matters.
공시 • May 06Universe Pharmaceuticals INC Announces Board ChangesUniverse Pharmaceuticals INC announced that on April 24, 2023, Mr. David Sherman, the Directors of the Company, notified the Company of his resignation as a director of the Company and the chairman of the audit committee of the board of directors, effective May 2, 2023. On May 3, 2023, the Company’s board of directors appointed Mr. Yongping Yu as a director of the Company and the chairman of the nominating and corporate governance committee of the board of directors. The board of directors also appointed Mr. Ding Zheng, a director of the company and the then chairman of the nominating and corporate governance committee of the board of directors, as the chairman of the audit committee of the board of directors. The appointments intend to fill the vacancy created by Mr. David Sherman’s departure. Mr. Yongping Yu has served as one of the Company’s independent directors since May 2023. Mr. Yongping Yu has served as the General Manager of Zhuhai Qirong Venture Capital Investment Management Co. Ltd. since August 2019, a venture capital company focused on the healthcare industry. Mr. Yongping Yu served as a director and Executive Deputy General Manager of Xinhua Kangmei Health Think Tank Co. Ltd. from May 2017 to July 2019. From July 2015 to May 2017, Mr. Yongping Yu served as the General Manager of the Medical Data Division of Xinhua News Agency’s Big Data Business Department. From July 2014 to July 2015, Mr. Yongping Yu served as the Editor-in-Chief and General Manager of Xinhua Cyber Health, a WeChat official account, at Xinhua News Agency. From February 2011 to July 2014, Mr. Yongping Yu served as the Director of the Development Planning Department and Chief Physician of the Aviation General Hospital. From April 2004 to February 2011, Mr. Yongping Yu served as the Deputy Secretary-General of JiangXi Pharmaceutical Association. Mr. Yu obtained a Bachelor of Medicine degree from Nanchang University in the PRC in 1992 and obtained Bachelor of Arts degree in Chinese language and literature from Tsinghua University in the PRC in 1995.
공시 • Jan 31Universe Pharmaceuticals INC announced delayed 20-F filingOn 01/30/2023, Universe Pharmaceuticals INC announced that they will be unable to file their next 20-F by the deadline required by the SEC.
Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to US$1.69, the stock trades at a trailing P/E ratio of 6.2x. Average trailing P/E is 17x in the Pharmaceuticals industry in the US. Total returns to shareholders of 5.4% over the past year.
공시 • Dec 22Universe Pharmaceuticals INC Announces Inclusion of Six Products into the First Edition of Catalogue of Medicine for Patients Infected with COVID-19Universe Pharmaceuticals INC announced that six varieties of the Company's products were included in the First Edition of Catalogue of Medicine for Patients Infected with COVID-19 which was published by Beijing Health Commission on December 12, 2022. The included products are Banlangen Granules, Strong Loquat Extract, Pediatric Paracetamol, Vitamin C Yinqiao Tablets, Acetaminophen Tablets and Metamizole Sodium Tablets. The Catalogue supplements the list of recommended medicine in the Ninth Edition of the National Diagnosis and Treatment Plan. The Catalogue recommends 67 types of traditional Chinese medicine products for six different types ofmedical symptoms, such as fever and sore throat, and recommends 41 varieties of western medicine products for four types of clinical symptoms, such as cough and expectoration. In addition to hospitals, patients can also purchase medicines included in the Catalogue from channels such as retail pharmacies and e-commerce platforms according to their own needs.
Valuation Update With 7 Day Price Move • Nov 30Investor sentiment improved over the past weekAfter last week's 18% share price gain to US$1.76, the stock trades at a trailing P/E ratio of 6.5x. Average trailing P/E is 16x in the Pharmaceuticals industry in the US. Total loss to shareholders of 19% over the past year.
공시 • Nov 15Universe Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementUniverse Pharmaceuticals INC announced that the Company received a written notification (the “Notification Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) on November 9, 2022, informing the Company that it has regained compliance with the Nasdaq’s minimum bid price requirement and the matter is closed. On July 15, 2022, the Company was notified by Nasdaq its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive business days under Nasdaq Listing Rules 5450(a)(1) and 5810(c)(3)(A), and was provided 180 calendar days, or until January 11, 2023 to regain compliance. The Notification Letter the Company received from Nasdaq on November 9, 2022 noted that the Company evidenced a closing bid price of its ordinary shares at or greater than the $1.00 per share minimum requirement for the last 10 consecutive business days, from October 26, 2022 through November 8, 2022. Nasdaq stated that accordingly, the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1).
Valuation Update With 7 Day Price Move • Oct 21Investor sentiment improved over the past weekAfter last week's 27% share price gain to US$1.05, the stock trades at a trailing P/E ratio of 3.9x. Average trailing P/E is 13x in the Pharmaceuticals industry in the US. Total loss to shareholders of 55% over the past year.
공시 • Aug 30Universe Pharmaceuticals INC, Annual General Meeting, Sep 23, 2022Universe Pharmaceuticals INC, Annual General Meeting, Sep 23, 2022, at 10:00 China Standard Time. Location: 265 Jingjiu Avenue, Jinggangshan Economy and Technology Development Zone, Ji'an City Ji'an City China Agenda: To re-elect directors; to approve of the proposed filing of a shelf registration statement on Form F-3 registering the Company's ordinary shares, preferred shares, debt securities, warrants, rights and units of up to $200 million; to re-designate 10,000,000 authorized but unissued ordinary shares of the Company; to adopt a second amended and restated memorandum and articles of association; to authorize board of directors to effect a consolidation of the Company's authorized and issued share capital; to consider subject to approval by the shareholders of the Share Consolidation, and entirely conditional upon the effectiveness of the Share Consolidation, with effect as of the date the Company's board of directors may determine in its sole discretion, the Company adopt a third amended and restated memorandum of association.
Reported Earnings • Aug 18First half 2022 earnings released: EPS: US$0.08 (vs US$0.44 in 1H 2021)First half 2022 results: EPS: US$0.08 (down from US$0.44 in 1H 2021). Revenue: US$24.2m (flat on 1H 2021). Net income: US$1.73m (down 76% from 1H 2021). Profit margin: 7.2% (down from 29% in 1H 2021).
공시 • Jul 20Universe Pharmaceuticals Inc Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyUniverse Pharmaceuticals INC announced that the Company received a written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) on July 15, 2022, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's ordinary shares for the 30 consecutive business days from June 1, 2022 to July 14, 2022, the Company no longer meets the minimum bid price requirement. The Notification Letter does not impact the Company's listing on the Nasdaq Global Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until January 11, 2023, to regain compliance with Nasdaq Listing Rule 5450(a)(1). To regain compliance, the Company's ordinary shares must have a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. In the event the Company does not regain compliance by January 11, 2023, the Company may be eligible for additional time to regain compliance or may face delisting.
Seeking Alpha • Jul 19Universe pharmaceuticals receives Nasdaq notification regarding minimum bid price deficiencyUniverse Pharmaceuticals (NASDAQ:UPC) received Nasdaq notification on July 15, 2022, notifying the company that it is not in compliance with the minimum bid price requirement. The company has 180 days to regain compliance. If the company does not regain compliance by January 11, 2023, the company may be eligible for additional time to regain compliance or may face delisting. The Company intends to monitor the closing bid price of its ordinary shares and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse share split of its outstanding ordinary shares, to regain compliance.
Valuation Update With 7 Day Price Move • Mar 12Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to US$1.09, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 20x in the Pharmaceuticals industry in the US.
분석 기사 • Feb 21Improved Earnings Required Before Universe Pharmaceuticals INC (NASDAQ:UPC) Shares Find Their FeetWhen close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 17x, you may...
Reported Earnings • Feb 02Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: US$0.60 (up from US$0.47 in FY 2020). Revenue: US$48.0m (up 56% from FY 2020). Net income: US$11.3m (up 50% from FY 2020). Profit margin: 24% (down from 25% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates.
Valuation Update With 7 Day Price Move • Jan 25Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to US$1.36, the stock trades at a trailing P/E ratio of 3.1x. Average trailing P/E is 23x in the Pharmaceuticals industry in the US.
Valuation Update With 7 Day Price Move • Dec 03Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to US$1.88, the stock trades at a trailing P/E ratio of 4.2x. Average trailing P/E is 23x in the Pharmaceuticals industry in the US.
분석 기사 • Aug 10We Think That There Are Some Issues For Universe Pharmaceuticals (NASDAQ:UPC) Beyond Its Promising EarningsUniverse Pharmaceuticals INC's ( NASDAQ:UPC ) healthy profit numbers didn't contain any surprises for investors. We...
Reported Earnings • Aug 04First half 2021 earnings released: EPS US$0.44 (vs US$0.32 in 1H 2020)The company reported a solid first half result with improved earnings and revenues, although profit margins were weaker. First half 2021 results: Revenue: US$24.3m (up 48% from 1H 2020). Net income: US$7.15m (up 41% from 1H 2020). Profit margin: 29% (down from 31% in 1H 2020). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Jul 23Investor sentiment improved over the past weekAfter last week's 40% share price gain to US$3.83, the stock trades at a trailing P/E ratio of 8.1x. Average trailing P/E is 21x in the Pharmaceuticals industry in the US.
Valuation Update With 7 Day Price Move • Jun 30Investor sentiment improved over the past weekAfter last week's 22% share price gain to US$3.70, the stock trades at a trailing P/E ratio of 7.8x. Average trailing P/E is 22x in the Pharmaceuticals industry in the US.
Valuation Update With 7 Day Price Move • Apr 14Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to US$4.09, the stock trades at a trailing P/E ratio of 8.7x. Average trailing P/E is 27x in the Pharmaceuticals industry in the US.